Managers / Q1 2019 · view latest →
Essex Woodlands Management, Inc.
CIK 0001542339 · 21 WATERWAY AVE, STE 150, THE WOODLANDS, TX, 77380 · 281-364-1555
Summary
Essex Woodlands Management, Inc. reported $201M in U.S.-listed holdings across 8 positions for Q1 2019.
The portfolio is heavily concentrated: Eyepoint alone accounts for 37.3% of reported value.
The book was largely unchanged from Q4 2018.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 60.0% · $120M
- Other · 40.0% · $80M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2018 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CORIUM | HELD | +0 | 0 | +$126,000 | $3M |
| EYEPOINT | HELD | +5.3K | 41.91M | −$4M | $75M |
| RVNCEURREVANCE THERAPEUTICS INC | HELD | +0 | 3.34M | −$39M | $53M |
| 4875MEDICINOVA INC | HELD | +0 | 1.17M | −$5M | $10M |
| ENDOLOGIX INC | HELD | +0 | 1.26M | −$4M | $1M |
| AXGNAXOGEN INC | HELD | +0 | 2.74M | +$2M | $58M |
| ACURACURA PHARMACEUTICALS INC | HELD | +0 | 1.96M | +$137,000 | $352,000 |
| CATALYST | HELD | +0 | 78.6K | +$15,000 | $640,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2019
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | EYEPOINT | COM | 37.35% | $75M | 41.91M |
| 2 | AXGNAXOGEN INChistory → | COM | 28.73% | $58M | 2.74M |
| 3 | RVNCEURREVANCE THERAPEUTICS INChistory → | COM | 26.22% | $53M | 3.34M |
| 4 | 4875MEDICINOVA INChistory → | COM | 4.82% | $10M | 1.17M |
| 5 | CORIUM | COM | 1.74% | $3M | 0 |
| 6 | ENDOLOGIX INC | COM | 0.64% | $1M | 1.26M |
| 7 | CATALYST | COM | 0.32% | $640,000 | 78.6K |
| 8 | ACURACURA PHARMACEUTICALS INC | COM | 0.18% | $352,000 | 1.96M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $251M | 5 | May 4, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $318M | 6 | Feb 4, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $307M | 6 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $279M | 6 | Aug 7, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $347M | 6 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $433M | 7 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $350M | 7 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $307M | 7 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $345M | 7 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $404M | 7 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $113M | 6 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $132M | 6 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $173M | 7 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $179M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $242M | 7 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $242M | 9 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $414M | 9 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $445M | 10 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $451M | 9 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $677M | 9 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $640M | 9 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $385M | 8 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $188M | 8 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $204M | 8 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $155M | 8 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $214M | 8 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $161M | 6 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $173M | 6 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $201M | 8 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $251M | 8 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.